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To examine the role of orexin-1 and orexin-2 receptor activity on ethanol
self-administration, compounds that differentially target orexin (OX) receptor subtypes
were assessed in various self-administration paradigms using high-drinking rodent models.
Effects of the OX1 antagonist SB334867, the OX2 antagonist LSN2424100, and the
mixed OX1/2 antagonist almorexant (ACT-078573) on home cage ethanol consumption
were tested in ethanol-preferring (P) rats using a 2-bottle choice procedure. In separate
experiments, effects of SB334867, LSN2424100, and almorexant on operant ethanol
self-administration were assessed in P rats maintained on a progressive ratio operant
schedule of reinforcement. In a third series of experiments, SB334867, LSN2424100, and
almorexant were administered to ethanol-preferring C57BL/6J mice to examine effects
of OX receptor blockade on ethanol intake in a binge-like drinking (drinking-in-the-dark)
model. In P rats with chronic home cage free-choice ethanol access, SB334867 and
almorexant significantly reduced ethanol intake, but almorexant also reduced water
intake, suggesting non-specific effects on consummatory behavior. In the progressive
ratio operant experiments, LSN2424100 and almorexant reduced breakpoints and ethanol
consumption in P rats, whereas the almorexant inactive enantiomer and SB334867 did
not significantly affect the motivation to consume ethanol. As expected, vehicle-injected
mice exhibited binge-like drinking patterns in the drinking-in-the-dark model. All three
OX antagonists reduced both ethanol intake and resulting blood ethanol concentrations
relative to vehicle-injected controls, but SB334867 and LSN2424100 also reduced sucrose
consumption in a different cohort of mice, suggesting non-specific effects. Collectively,
these results contribute to a growing body of evidence indicating that OX1 and OX2
receptor activity influences ethanol self-administration, although the effects may not be
selective for ethanol consumption.
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INTRODUCTION
Orexins A and B are neuropeptides synthesized in neurons origi-
nating in the lateral hypothalamus (LH) that project throughout
the brain and bind to two widely expressed G-protein coupled
receptors, orexin-1 (OX1) and orexin-2 (OX2). OX1 receptors
selectively bind orexin A, whereas OX2 receptors bind orexin A
and B with equal affinity (Sakurai et al., 1998). This neuropep-
tide system plays an established role in numerous behavioral
and regulatory functions including sleep, arousal, and feeding
behavior (Willie et al., 2001; Sakurai, 2002). While orexin neu-
rons in the dorsomedial hypothalamus are believed to regulate
arousal and stress responses, orexin neurons within the LH are
hypothesized to play a role in regulating reward processing for
natural rewards as well as drugs of abuse (Harris and Aston-Jones,
2006). This has led to the suggestion that the orexin system is
involved in addiction (for review, see Sharf et al., 2010; Mahler
et al., 2012). Although evidence previously supported functional
differences between the two receptors, with OX2 receptor activ-
ity more closely related to arousal and OX1 receptor activity more
closely associated with reward (Aston-Jones et al., 2010), more
recent research has revealed a role for OX2 receptors in reward
processes as well (Shoblock et al., 2011; Brown et al., 2013).
While a growing body of literature has shown that the
orexin system interacts with drug-seeking behavior induced by
numerous drugs of abuse such as cocaine, nicotine, and opi-
ates (reviewed by Mahler et al., 2012), the orexin system also
has been implicated in the motivational properties of ethanol.
Administration of orexin A into the paraventricular nucleus
within the LH resulted in elevated ethanol consumption in
Sprague-Dawley rats (Schneider et al., 2007). Orexin antagonists
that target both OX1 and OX2 receptors have been shown to
influence ethanol consumption (Kim et al., 2012). For example,
systemic administration of the OX1 receptor antagonist SB334867
reduced ethanol intake and preference in Sprague-Dawley rats
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(Moorman and Aston-Jones, 2009). This same antagonist has
been shown to reduce relapse drinking, operant responding, and
both cue- and stress-induced reinstatement in other rat strains
(Richards et al., 2008; Dhaher et al., 2010; Jupp et al., 2011).
The OX2 receptor antagonist JNJ-10397049 also reduced ethanol
self-administration and expression of ethanol conditioned place
preference (Shoblock et al., 2011). Central administration of the
OX2 receptor antagonist TCS-OX2-29 reduced ethanol intake
but did not alter cue-induced reinstatement of responding for
ethanol (Brown et al., 2013). Although the dual OX1/2 receptor
antagonist almorexant has been shown to reduce operant ethanol
self-administration when injected either systemically or directly
into the ventral tegmental area (VTA; Srinivasan et al., 2012),
effects of dual antagonism of both orexin receptors on ethanol
consumption have not been as thoroughly explored.
There is some evidence to suggest that orexin antagonists
may be particularly effective in subjects that show a high pref-
erence for ethanol. For example, an OX1 receptor antagonist
was more effective in reducing ethanol consumption among
outbred Sprague-Dawley rats that demonstrated high vs. low
ethanol preference (Moorman and Aston-Jones, 2009). Further,
several studies that reported orexin antagonist-induced reduc-
tions in ethanol self-administration used rats selectively bred
for high ethanol preference (Lawrence et al., 2006; Dhaher
et al., 2010; Jupp et al., 2011; Brown et al., 2013). Taken
together, these results suggest that blocking orexin activity in
the brain may be particularly effective in reducing ethanol
consumption under conditions in which subjects exhibit a
high propensity for ethanol self-administration. The present
study was designed to characterize the relative contributions
of OX1 and OX2 receptor-mediated signaling in modulating
ethanol consumption using three different self-administration
paradigms in high-drinking rodents. The OX1 receptor antag-
onist SB334867 (Smart et al., 2001) is >1000-fold selective
for OX1 over OX2 receptors, whereas the novel OX2 receptor
antagonist N-((1H-imidazol-2-yl)methyl)-N-([1,1′-biphenyl]-2-
yl)-4-fluorobenzenesulfonamide hydrochloride (LSN2424100)
is >200-fold selective for OX2 over OX1 receptors (Fitch et al.,
2014). The dual OX1/OX2 antagonist almorexant (ACT-078573;
Brisbare-Roch et al., 2007), which is approximately 1.3-fold OX2-
preferring (Fitch et al., 2014), was also tested for comparison
to the more selective compounds. Each of these compounds
was tested in three different experiments: home cage free-choice
drinking in female P rats, progressive ratio operant responding
maintained by ethanol in female P rats, and ethanol consump-
tion in a binge-drinking model (drinking-in-the-dark) in male
C57BL/6J mice. Some of the P rat experiments included either
the inactive enantiomer of almorexant as a negative control or
naltrexone as a positive control.
MATERIALS AND METHODS
SUBJECTS
All experiments were conducted in compliance with the Guide
for the Care and Use of Laboratory Animals under proto-
cols approved by the local Institutional Animal Care and Use
Committees. Rat experiments were conducted in adult female
selectively bred Alcohol-Preferring (P) rats generously supplied
by the Indiana University School of Medicine (maintained as a
private colony at Taconic Inc., Germantown, NY). For the home
cage ethanol consumption studies, a total of 32 female P rats
were individually housed with 24-h ad libitum access to 15%
(v/v) ethanol, water, and food. All 32 P rats had chronic access
to ethanol in the home cage for approximately 8–14 months
before the current studies were conducted. P rats were divided
into 3 groups. One group (n = 10) was used to test the effects
of SB334867 and a second group (n = 11) was used to test the
effects of LSN2424100 (one rat was excluded from the experiment
due to low baseline drinking). A within-subjects experimental
design was used to test the OX1 and OX2 receptor antagonists.
These rats, along with another group of 11 (i.e., all 32 P rats)
were tested in the almorexant study using a between-subjects
design (n = 8/dose).
A separate cohort of female P rats (n = 10) used in operant
experiments were pair-housed with food and water available ad
libitum and maintained on a 12-h light/dark cycle (lights on at
6:00 AM). All operant procedures were conducted during the
light phase (between 10 AM and 4 PM). In order to reduce
the total number of animals used, within-subjects designs were
employed for the operant and home cage consumption exper-
iments. To avoid potential carryover effects, a 3–4 day washout
period was imposed between different drug doses, and a 4–7 day
washout period was included between the different drug experi-
ments. Baseline performance of the rats (operant and home cage
consumption) was monitored on non-dose days to confirm that
ethanol intake returned to baseline levels prior to testing.
For the mouse experiments, a total of 166 adult male C57BL/6J
mice (Jackson Laboratories, Bar Harbor, ME) were used in
the binge drinking experiments, which were conducted using a
between-subjects design. Mice were individually housed through-
out experimentation under a 12-h reverse light/dark cycle (lights
off at 8:00 AM). All testing occurred during the dark cycle.
DRUGS
N-((1H-imidazol-2-yl)methyl)-N-([1,1′-biphenyl]-2-yl)-4-fluor
obenzenesulfonamide hydrochloride (LSN2424100), SB334867,
(S)-almorexant (ACT-078573), and the inactive (R) enantiomer
of almorexant were synthesized at Lilly Research Laboratories
(Indianapolis, IN). Naltrexone hydrochloride was purchased
from Sigma Aldrich (St. Louis, MO). For rat experiments, the
OX1 antagonist SB334867 was dissolved in a vehicle of 10%
(2-hydroxypropyl)-β-cyclodextrin, 2% dimethyl sulfoxide, and
0.05% lactic acid in water, and administered by intraperitoneal
(i.p.) injection in a dose volume of 1ml/kg. The OX2 antagonist
LSN2424100 was suspended in 1% carboxymethyl cellulose,
0.25% polysorbate-80 and 0.05% Dow antifoam in water, and
administered by i.p. injection in a dose volume of 1ml/kg. The
mixed OX1/2 antagonist almorexant, and its inactive enantiomer,
were dissolved in a 20%Captisol solution and administered orally
(p.o.) in a dose volume of 1ml/kg. Naltrexone was dissolved in
water with the addition of 15μl 85% lactic acid.
For mouse experiments, SB334867 was dissolved using 0.01%
polysorbate-80 in saline. Almorexant was dissolved in 20%
Captisol in water. LSN2424100 was suspended using 1% car-
boxymethyl cellulose and 0.25% polysorbate-80 in water. All
compounds were administered by i.p. injection at a dose volume
of 10ml/kg.
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PROCEDURE
Home cage 2-bottle choice drinking in P rats
P rats were housed individually in TSE LabMaster cages (TSE
Systems, Bad Homburg, Germany) with food, water, and 15%
ethanol (v/v) available at all times. Water and ethanol intake (in
ml) were measured once every 5min throughout the 12-h dark
cycle and recorded for later analysis. In the first experiment, rats
(n = 10) received vehicle, 3, 10, or 30mg/kg SB334867 (i.p.),
60min before onset of the 12-h dark phase of the light-dark cycle,
using a within-subjects design. In the second experiment, rats
(n = 10) received vehicle, naltrexone (10mg/kg), or LSN2424100
at doses of 10 or 30mg/kg (i.p.), 60min before onset of the
12-h dark phase, using a within-subjects design (one rat was
excluded from the experiment due to low baseline drinking). In
the third experiment, rats (n = 32) received vehicle, naltrexone
(10mg/kg), or S-almorexant at doses of 60 or 100mg/kg (p.o.),
60min before onset of the dark cycle, using a between-subjects
design. Naltrexone was included in the study design as a positive
control, since this dose of naltrexone has been shown to effectively
reduce ethanol consumption in P rats under these testing con-
ditions. For all experiments, a 60-min pre-treatment period was
chosen so that the onset of the dark cycle roughly coincided with
the time at which maximal brain concentrations were achieved
(data not reported). Consumption of water and ethanol was mea-
sured during the first 3 h of the dark cycle, based on the short
half-lives and high metabolism of the compounds.
Operant progressive ratio responding in P rats
P rats were trained and tested 5 days per week in standard
rat operant chambers (Med Associates, St. Albans, VT), housed
within sound attenuating boxes. Operant chambers measured
30.5 × 24.1 × 21 cm, with clear Plexiglas front and back walls,
modular aluminum sidewalls, a metal bar floor and Plexiglas ceil-
ing. A food cup was located in the center of one sidewall with
retractable levers on either side of the food cup. A liquid dipper
device allowed the delivery of 0.1ml of 15% ethanol (v/v) into
the food cup. A computer running the MED-IV software package
(Med-Associates, St. Albans, VT) controlled stimulus presenta-
tions and recorded lever presses. Once subjects were trained to
lever press for ethanol reinforcement on a fixed ratio-1 (FR1)
schedule of reinforcement, the response requirement for each
reinforcement was slowly increased to FR2 and then FR3 over
1–2 weeks. When rats demonstrated a stable level of respond-
ing on the FR3 schedule, progressive ratio testing began. The
progressive ratio schedule involved increasing response require-
ments within each session. The response requirement increased
from 1 to 2 after three ethanol presentations, and continued to
increase by two after every three ethanol presentations (see Rodd
et al., 2003). Experimental sessions terminated after 60min. Total
responses on the active and inactive levers, breakpoints [defined
as the highest fixed ratio (FR) value reached during the session],
and the amount of ethanol consumed (ml; converted to g/kg)
were recorded for analysis.
Experiments were conducted using a within-subject design,
with 3–4 days washout between administration of different doses,
which were counterbalanced using a Latin square design. One
group of n = 10 rats was used to test the effects of SB334867,
LSN2424100, and almorexant on operant responding maintained
on a progressive ratio schedule, in separate experiments. Drugs
were administered two days per week (Tues and Fri) to allow for
washout between subsequent doses. Rats received vehicle, 3, 10, or
30mg/kg SB334867 (i.p., 30min prior to the session); vehicle, 3,
10, or 30mg/kg LSN2424100 (i.p., 30min prior to the session); or
vehicle, 10, 30, or 60mg/kg almorexant or 60mg/kg of the inac-
tive enantiomer of almorexant (p.o., 60min prior to the session).
On all other days, rats received progressive ratio operant testing
without any drug treatments to maintain operant performance
and confirm return to baseline behaviors. One rat was excluded
from testing 60mg/kg almorexant due to observation of a skin
rash not related to the study drug.
Binge drinking in C57BL/6J mice
One week prior to ethanol intake testing, mice were given daily
saline injections (i.p.) to acclimate them to handling and injec-
tion procedures. Ethanol consumption was assessed using a 4-day
drinking-in-the-dark (DID) paradigm during which the water
bottle in the home cage was replaced with a single bottle of
ethanol (20% v/v) starting 3 h after the onset of the dark cycle.
This procedure has been shown to produce high blood ethanol
concentrations (BECs) resulting from high levels of ethanol con-
sumption in a relatively short period of time (Rhodes et al.,
2005). On the first three days, animals were injected with saline
or vehicle 30min prior to a 2-h period of access to ethanol. On
the 4th day, drugs were administered via i.p. injection 30min
prior to the test session, which was extended to 4 h. One cohort
of mice was administered vehicle, 3, 10, or 30mg/kg SB334867
(n = 10/dose). A second cohort of mice was tested with vehicle,
15, 30, or 60mg/kg LSN2424100 (n = 9–10/dose). A third cohort
of animals was given vehicle, 25, 50, or 100mg/kg almorexant
(n = 10/dose). In order to assess resulting BECs, immediately
upon removal of ethanol bottles, blood samples were collected
from the retro-orbital sinus and centrifuged. The plasma was
assayed using an Analox Instruments analyzer (Lunenburg, MA).
In order to assess the specificity of drug effects on ethanol
consumption, an additional group of ethanol-naïve animals was
tested with sucrose solution (1% w/v) in the same DID paradigm
(Days 1–3: 2-h access with saline injections; Day 4: 4-h test ses-
sion with drug pretreatment). On the 4th day, vehicle, 3, 10,
or 30mg/kg (n = 6–7/dose) SB334867 was administered prior
to the 4-h access period. During a subsequent week of testing,
these same mice were administered either vehicle or 100mg/kg
almorexant (n = 14/dose) before the 4-h intake session. In a
separate cohort of mice, vehicle or 60mg/kg LSN2424100 (n =
9–10/dose) was administered prior to the 4-h test.
Data analysis
For subjects treated with SB334867 and LSN2424100 in the home
cage drinking studies, ethanol and water intake (g/kg and ml/kg,
respectively) during the first 3 h of the dark cycle were calcu-
lated and analyzed separately using repeated measures analyses
of variance (ANOVAs), with drug dose as a within-subjects factor
(IBM SPSS Statistics, Armonk, NY). The positive control, naltrex-
one, was compared with vehicle using an independent samples
t-test. For subjects treated with almorexant, ethanol and water
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intake were analyzed using ANOVAs with drug dose as a between-
subjects factor. The positive control, naltrexone, was compared
with vehicle using an independent samples t-test. All significant
within-subject effects were further explored using paired-samples
t-tests, except for the between-subjects almorexant study, for
which Tukey’s HSD test was used.
For subjects treated with SB334867 and LSN2424100 in the
operant progressive ratio paradigm, total active lever responses,
total ethanol consumption (g/kg), and breakpoints (highest FR
value reached) were calculated and analyzed via repeated mea-
sures ANOVAs, with dose as a within-subjects factor. The negative
control, R-almorexant, was compared with vehicle using a sep-
arate paired samples t-test. All significant within-subject effects
were further explored using paired-samples t-tests. Total respond-
ing on the inactive levers was negligible, so those data were not
analyzed.
For the mouse drinking studies, ethanol consumption dur-
ing each 4-h test session was expressed in g/kg and subjected
to a One-Way ANOVA with dose as a between-subjects factor.
BEC data (mg/dl) were analyzed similarly. Sucrose data were
expressed as ml/kg and subjected to independent samples t-
tests. Because only the doses of LSN2424100 and almorexant that
reduced ethanol consumption were tested with sucrose, the 3
and 10mg/kg SB334867 data were excluded from the analysis for
consistency across compounds.
RESULTS
HOME CAGE 2-BOTTLE CHOICE DRINKING IN P RATS
SB334867
In the first experiment, rats received vehicle, 3, 10, or 30mg/kg
SB334867. A significant main effect of dose was observed
[F(3, 27) = 4.36, p < 0.05]. Follow-up paired-samples t-tests
indicated that the 10 and 30mg/kg doses of SB334867 signif-
icantly reduced ethanol intake relative to vehicle (ps < 0.05
and 0.01, respectively; Figure 1A, filled bars). No significant
effects emerged in the analysis of water consumption (p > 0.05;
Figure 1A, open bars).
LSN2424100
In the second experiment, rats received vehicle, 10, or 30mg/kg
LSN2424100, or 10mg/kg naltrexone. As shown in Figure 1B,
LSN2424100 did not significantly affect ethanol intake (p > 0.05;
filled bars). However, a paired-samples t-test revealed that nal-
trexone significantly attenuated ethanol intake [t(9) = 3.31, p <
0.015]. Neither LSN2424100 nor naltrexone produced significant
effects on water intake (ps> 0.05; Figure 1B, open bars).
Almorexant
In the third experiment, rats received vehicle, 60 or 100mg/kg
almorexant, or 10mg/kg naltrexone in a between-subjects design.
Almorexant significantly reduced ethanol intake [F(2, 20) = 3.12,
p = 0.05]. A post-hoc Tukey’s HSD test revealed that only the
100mg/kg dose of almorexant significantly affected ethanol
intake, while effects at the 60mg/kg dose were not statis-
tically significant (Figure 1C, filled bars). An independent-
samples t-test revealed that naltrexone also significantly reduced
ethanol consumption [t(13) = 3.08, p < 0.01; Figure 1C, filled
FIGURE 1 | Home cage 2-bottle choice drinking in P rats during the first
3 h of the dark cycle. (A) SB334867 (n = 10) reduced ethanol intake at doses
of 10 and 30mg/kg, without altering water consumption. (B) LSN2424100
(n = 10) did not significantly influence ethanol orwater intake. Naltrexonewas
included as a positive control at a dose (10mg/kg) that selectively reduced
ethanol intake (indicated by #, p < 0.05). (C)Almorexant (n = 8/dose) reduced
ethanol intake at the 100mg/kg dose while also suppressing water intake at
the 60 and 100mg/kg doses. Naltrexone was included as a positive control at
a dose (10mg/kg) that selectively reduced ethanol intake (indicated by #,
p < 0.05). Filled bars indicate ethanol consumption (g/kg) on the left y-axis;
open bars indicate water consumption (ml/kg) on the right y-axis. ∗ indicates
significant difference (p < 0.05) relative to vehicle-treated controls.
bars]. Almorexant significantly reduced home cage water intake
[F(2, 21) = 10.60, p < 0.01; Figure 1C, open bars]. A post-hoc
Tukey’s HSD test revealed that both the 60 and 100mg/kg doses of
almorexant significantly reduced water consumption (ps< 0.01).
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OPERANT PROGRESSIVE RATIO RESPONDING IN P RATS
SB334867
Although a trend toward efficacy was observed for SB334867
on progressive ratio responding for ethanol, statistical analysis
revealed no significant effects of the drug on the number of active
lever responses (data not shown), breakpoints (Figure 2A), or
total ethanol consumption (Figure 2B; all ps> 0.05).
LSN2424100
The OX2 antagonist LSN2424100 significantly reduced break-
points [main effect of dose: F(3, 36) = 4.61, p < 0.01] and
resulting ethanol consumption [main effect of dose: F(3, 36) =
6.59, p < 0.01]. Post-hoc tests indicated that the 30mg/kg dose
was significantly different from vehicle (see Figures 2C,D).
LSN2424100 also significantly reduced active lever presses
[F(3, 27) = 3.67, p < 0.05; data not shown].
Almorexant
Almorexant significantly reduced active lever presses [main effect
of dose: F(3, 24) = 25.26, p < 0.001]. Paired-samples t-tests indi-
cated that doses of 10, 30, and 60mg/kg significantly reduced
active lever responding (ps < 0.05; data not shown). A paired-
samples t-test indicated that the inactive enantiomer of almorex-
ant did not significantly affect responses on the active lever (p >
0.05). Similarly, almorexant significantly reduced breakpoints
[F(3, 24) = 32.32, p < 0.001], with significant effects at doses of
FIGURE 2 | Operant progressive ratio responding in P rats. SB334867
(n = 8) did not significantly reduce breakpoints (A) or ethanol consumption
(B) maintained by a progressive ratio operant schedule of reinforcement. The
30mg/kg dose of LSN2424100 (n = 10) reduced the motivation to consume
ethanol as indicated by reductions in breakpoints (C) and corresponding
ethanol consumption (D). (E,F) Almorexant (n = 10) reduced breakpoints and
ethanol consumption at all doses tested (10, 30, and 60mg/kg) doses. As
expected, the inactive enantiomer (60mg/kg) did not significantly affect
progressive ratio operant responding for ethanol or ethanol consumption.
Breakpoint was defined as the highest fixed ratio value reached by rats during
the operant session. ∗ indicates significant difference (p < 0.05) relative to
vehicle-treated controls.
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10 (p < 0.01), 30 and 60mg/kg (ps < 0.001; Figure 2E), while
the inactive enantiomer did not (p > 0.05). Almorexant also sig-
nificantly attenuated ethanol consumption [F(3, 24) = 32.29, p <
0.001] at doses of 10 (p < 0.01), 30, and 60mg/kg (ps < 0.001;
Figure 2F). A paired-samples t-test indicated that the inactive
R-enantiomer of almorexant did not significantly affect ethanol
consumption (p > 0.05).
BINGE DRINKING IN C57BL/6J MICE
SB334867
Analysis revealed a main effect of dose [F(3, 36) = 3.6, p < 0.05],
with the 30mg/kg SB334867 dose reducing ethanol intake rela-
tive to vehicle-injected controls (Figure 3A). BEC data indicated
a similar pattern, with a main effect of dose emerging [F(3, 36) =
4.4, p < 0.05]. While post-hoc tests revealed no significant dif-
ferences between vehicle and any doses of SB334867, pairwise
comparisons indicated that the 30mg/kg dose resulted in lower
BECs than both the 3 and 10mg/kg doses (Figure 3B). Analysis
of sucrose consumption (Figure 3C) revealed that 30mg/kg
SB334867 suppressed sucrose intake relative to vehicle [t(11) =
2.74, p < 0.05].
LSN2424100
Analysis of ethanol intake on the test day revealed a main effect
of dose [F(3, 35) = 4.3, p < 0.05], with the 60mg/kg dose reduc-
ing ethanol consumption relative to vehicle-injected control mice
(Figure 3D). This reduction was mirrored in BEC data [main
effect of dose: F(3, 35) = 6.1, p < 0.01], with the 60mg/kg dose
resulting in lower BECs (Figure 3E). Analysis of sucrose con-
sumption data (Figure 3F) revealed a significant suppression in
mice administered the 60mg/kg dose relative to vehicle [t(17) =
8.76, p < 0.001].
Almorexant
Analysis revealed a main effect of dose [F(3, 36) = 5.0, p < 0.01],
with the 100mg/kg dose reducing ethanol intake relative to
vehicle-injected controls (Figure 3G). Analysis of BEC data also
revealed a main effect of dose [F(3, 36) = 9.0, p < 0.001], with
both the 50 and 100mg/kg doses of almorexant resulting in lower
BECs than vehicle-treated control mice (Figure 3H). Analysis
of sucrose consumption data revealed a trend (p = 0.085) for
almorexant to reduce sucrose consumption, an effect that did not
reach statistical significance (Figure 3I).
DISCUSSION
Data from the present series of experiments provide evidence
that blockade of OX1 and OX2 receptors reduces ethanol self-
administration in a variety of high-drinking rodent paradigms,
although observed effects were dependent on the specific proce-
dures used to evaluate ethanol-seeking behavior. The OX1 recep-
tor antagonist reduced home cage ethanol drinking in rats and
binge-like drinking in mice, without influencing progressive ratio
operant responding in rats. Blockade of OX2 receptors did not
alter home-cage ethanol intake in rats, but did lower breakpoints
and reduce ethanol consumption in the progressive ratio proce-
dure in P rats as well as reducing binge-like drinking inmice. Dual
antagonism of OX1 andOX2 receptors resulted in reduced ethanol
consumption in rats and mice in addition to decreasing break-
points and ethanol consumption in the operant progressive ratio
model. Due to an established role for orexin in the regulation of
feeding behavior, it was important to assess the specificity of these
drug effects by measuring the ability of the these compounds
to alter consumption of another caloric solution. Indeed, results
from the present study indicated that some of the test compounds
also reduced sucrose consumption in mice.
The majority of previous work exploring the role of orexin
in ethanol reward has focused on blockade of OX1 receptors
with SB334867, with this compound typically reducing ethanol
self-administration (Lawrence et al., 2006; Richards et al., 2008;
Moorman and Aston-Jones, 2009; Jupp et al., 2011). In accor-
dance with these findings, we demonstrate here that SB334867
reduced home cage ethanol intake in P rats with a long history
of ethanol consumption. SB334867 has been previously shown to
reduce breakpoints in an operant progressive ratio procedure in
male iP rats (Jupp et al., 2011). In contrast, SB334867 did not sig-
nificantly alter breakpoints or corresponding ethanol consump-
tion in female P rats in the present study. It is unclear whether
this discrepancy can be attributed to sex differences, experimental
procedural differences, or differences between respective inbred
lines. In the current study, we reported for the first time that
SB334867 reduced binge-like ethanol intake in the drinking-in-
the-dark procedure in mice. Oddly, the BEC values reported in
the vehicle-injected mice were lower than expected given the high
ethanol consumption. This apparent disparity may be a conse-
quence of the long length of the testing period. Although not
assessed in the current study, different patterns of ethanol con-
sumption over the 4-h period may have resulted in different BEC
values. The dose of SB334867 that effectively reduced ethanol
intake also suppressed consumption of a 1% sucrose solution.
However, previous reports indicate that SB334867 did not affect
operant self-administration of a 5% sucrose solution (Richards
et al., 2008). It is tempting to speculate that self-administration
of the 1% sucrose solution used in the current experiments may
be more susceptible to disruption by OX antagonists because it
is less palatable to the mice than the 5% sucrose solution in
other studies. Further experiments will be required to explore
this possibility. Overall, the data reported herein complement and
extend previous literature reports demonstrating that SB334867
attenuates ethanol self-administration.
Although previous work has examined OX2 receptor involve-
ment in operant ethanol self-administration and reinstatement
procedures, the present study is the first to examine the effects of
OX2 antagonism on voluntary home cage ethanol consumption,
breakpoints in an operant progressive ratio procedure, and binge-
like ethanol drinking using the novel compound LSN2424100.
This OX2 antagonist did not alter ethanol consumption under
voluntary continuous access conditions in P rats but did reduce
breakpoints in the operant progressive ratio procedure, indicat-
ing reduced motivation to consume ethanol (Richardson and
Roberts, 1996) in alcohol-preferring rats. Consistent with the
reduction in operant breakpoints, LSN2424100 also decreased
ethanol intake in the progressive ratio model. Our data are
consistent with and complement earlier studies in which
other selective OX2 receptor antagonists (JNJ-10397049 and
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FIGURE 3 | Binge drinking in C57BL/6J mice. (A) SB334867 (n = 10)
reduced ethanol consumption at the 30mg/kg dose. (B) The 30mg/kg dose
of SB334867 resulted in lower BECs relative to both the 10 and 30mg/kg
doses (indicated by #, p < 0.05). (C) In a separate cohort of mice, SB334867
(30mg/kg) also reduced consumption of a 1% sucrose solution (n = 6–7). (D)
LSN2424100 (n = 10) reduced ethanol consumption at the 60mg/kg dose. (E)
The same dose resulted in lower BECs relative to vehicle-injected controls.
(F) The 60mg/kg dose of LSN2424100 significantly reduced consumption of
a 1% sucrose solution (n = 9–10). (G) Almorexant (n = 10) reduced ethanol
intake at the 100mg/kg dose. (H) Both the 50 and 100mg/kg doses of
almorexant resulted in lower BECs. (I) In a separate cohort of mice,
almorexant (100mg/kg) did not significantly reduce consumption of a 1%
sucrose solution (n = 14). ∗ indicates significant difference (p < 0.05) relative
to vehicle-injected controls.
TCS-OX2-29) decreased ethanol self-administration using other
operant paradigms in rats (Shoblock et al., 2011; Brown et al.,
2013).
Because it is well-known that OX antagonists reduce wakeful-
ness and suppress motor activity in general (e.g., Brisbare-Roch
et al., 2007), one might argue that the breakpoint reduction seen
in P rats is simply due to reduced locomotor activity. This is
unlikely given that the same dose of LSN2424100 (30mg/kg)
did not alter ethanol or water consumption in the home cage
drinking procedure reported here. Indeed, although OX receptor
antagonists facilitate sleep, they do not produce overt motor
impairment or sedative-like effects that are commonly associ-
ated with benzodiazepine receptor agonists, such as zolpidem
(Steiner et al., 2011). To the contrary, rats receiving OX recep-
tor antagonists, including those tested here, can perform oper-
ant and other motor tasks without any observable impairment
(Steiner et al., 2011; Rorick-Kehn et al., unpublished observa-
tions). That LSN2424100 reduced ethanol self-administration in
the operant progressive ratio assay, but not when ethanol was pro-
vided under unlimited access conditions, may suggest that OX2
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receptor-mediated signaling does not directly modulate ethanol
reward. Rather, OX2 receptors may be involved in modulat-
ing motivational circuits in the brain that underlie drug-seeking
behavior. Indeed, it is not uncommon for drugs to differentially
influence ethanol’s appetitive/motivational effects vs. consumma-
tory behavior (ethanol drinking per se) (e.g., Czachowski et al.,
2001, 2002). Alternatively, the differential efficacy of LSN2424100
in these two procedures may reflect the varying ethanol histories
of the rats tested in each model.
Inmice, ahighdoseofLSN2424100(60mg/kg) reducedethanol
consumption in the binge-like drinking procedure; however, the
same dose also suppressed sucrose consumption, suggesting that
thisdosewashighenough toproducenon-specificeffects.Whether
the suppression in sucrose intake reflects sleep-promoting effects
or a general reduction in consummatory behaviors cannot be
determined from the present series of studies. It is interesting
that the reduction in sucrose intake (∼85% reduction) was more
dramatic than the reduction in ethanol intake (∼36% reduction).
The reasons for this difference are not clear. Further work will be
necessary to better characterize the nature of these effects.
Antagonism of both OX1 and OX2 receptors by almorexant
reduced ethanol drinking in rats with continuous home-cage
access and in limited access binge-drinking in mice, and also
attenuated breakpoints and ethanol consumption in the pro-
gressive ratio model in rats. The data presented here confirm
and extend previous reports that almorexant suppressed operant
self-administration of both ethanol and sucrose in Long-Evans
rats (Srinivasan et al., 2012). Importantly, we demonstrate here
that the inactive enantiomer of almorexant did not suppress
breakpoints or ethanol self-administration in rats, indicating that
the effect was specific to blockade of OX1 and OX2 receptors
rather than unknown off-target pharmacological effects. Our data
in regard to the specificity of almorexant effects were mixed.
Specifically, almorexant reduced home-cage water drinking in
rats, suggesting potential non-specific effects on fluid consump-
tion, but it did not significantly attenuate sucrose intake in the
mice. Almorexant has previously been shown to reduce operant
responding for both ethanol and 5% sucrose when administered
systemically; however, when administered directly into the VTA,
effects were selective for ethanol (Srinivasan et al., 2012). In the
current report, it is unclear whether the reduced water intake
in rats, and the tendency for reduced sucrose intake in mice,
reflects non-specific consummatory effects or transient sedative
effects that may dissipate over the course of the extended drink-
ing session. Additional examination of the selectivity of effects of
the compounds tested in the present work, including assays of
locomotor activity, is warranted.
The drinking paradigms employed in the present study
involved different amounts of total ethanol exposure. Previous
studies have reported alterations in the orexin system follow-
ing long-term ethanol exposure. For example, chronic volun-
tary ethanol consumption (∼5 g/kg/day for 70 days) has been
reported to upregulate hypothalamic preproorexin mRNA in
P rats (Lawrence et al., 2006) whereas a reduction in orexin
mRNA has been reported after chronic ethanol consump-
tion (∼0.75–2.5 g/kg/day for 28 days) in Sprague-Dawley rats
(Morganstern et al., 2010). Several methodological differences
between the two studies may account for the seemingly contradic-
tory results, including differences in total daily ethanol exposure
(∼5 g/kg/day vs.∼0.75–2.5 g/kg/day), differences in genetic back-
ground (selectively bred P rats vs. Sprague-Dawley rats), and end-
point measured (preproorexin vs. orexin A mRNA). Nonetheless,
further studies will be required to determine the impact of long-
term ethanol exposure on the brain orexin system, and whether
adaptations in orexin signaling resulting from chronic ethanol
exposure contribute to the development of addiction. Indeed,
others have demonstrated that orexin-A stimulates dopamine
cell firing in the VTA, increases dopamine release in the pre-
frontal cortex (PFC), and potentiates PFC-evoked excitation of
VTA dopamine cells (Narita et al., 2006; Vittoz and Berridge,
2006; Moorman and Aston-Jones, 2010). Moreover, Borgland
et al. (2006) demonstrated that orexin signaling in the VTA
plays a critical role in synaptic plasticity associated with cocaine
addiction. The relevance of orexin-mediated signaling in critical
processes associated with addiction to drugs of abuse, including
ethanol, is beginning to be understood, and will likely be further
informed by the development and characterization of additional
selective tool compounds from different chemical scaffolds, such
as LSN2424100 reported here, that can be used to explore the rel-
ative roles of OX1- and OX2-receptor-mediated signaling. Future
studies in models of ethanol dependence using selective phar-
macological tools may provide valuable information about the
therapeutic potential of orexin antagonists for the treatment of
alcohol abuse and alcoholism.
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